powered by Pro Mach video

Pro Mach Web Site
ProCustomer Industry Leading Aftermarket Support
Allpax Retort Sterilization & Automation Systems
Axon Shrink & Stretch Sleeve Application Systems
Benchmark Food Distribution & Loading Systems
Brenton Case & Tray Packing & Robotic Systems
Currie by Brenton Conventional & Robotic Palletizing Systems
Dekka Case Taping Systems
Edson High Performance Case & Tray Packing Systems
EOL Packaging End of line Applications & Systems
EPI Labelers Flexible Packaging Labeling Systems
Federal Liquid Filling & Capping Systems
Flexible Packaging Flexible Packaging Applications & Systems
FLtecnics Rollstock Pouch Packaging Systems
Greydon Flexible Packaging Coding Systems
ID Technology Labeling, Marking & Coding Systems
Inever Stickpack & Sachet Packaging Systems
IPak Machinery Tray & Bliss Forming Systems
Jalbert Automation Services
KLEENLine Sanitary Product Handling Systems
LSI Pressure Sensitive Labeling Systems
Matrix Vertical Form Fill Seal Systems
NJM Packaging Pharmaceutical Packaging Systems
Orion Packaging Stretch & Pallet Wrapping Systems
Ossid Tray Packaging & Weighing Systems
Pace Packaging Bottle Unscrambling & Orienting Systems
Pacific Packaging Viscous Filling & Capping Systems
P.E. Labellers Decorative Labeling Systems
Rennco Vertical Bagging & Heat Sealing Systems
Roberts PolyPro Bottle & Box Handles & Application Systems
Shuttleworth Conveying & Material Handling Systems
Southern Packaging Rollstock Pouch Packaging Systems
Tekkra Shrink Bundling Systems
Texwrap Shrink Wrapping Systems
Toyo Jidoki Pre-Made Pouch Packaging Systems
Weiler Labeling Labeling & Serialization Systems
Wexxar/BEL Case Forming & Sealing Systems
Zalkin Americas Capping & Cap Handling Systems
Zalkin EMAA Capping & Cap Handling Systems
Zarpac Engineering & Integration Services

Powered by Pro Mach

Beefing Up FDA Authority over Drug Supply

Yet another drug has been found to be a counterfeit; the U.S. Food and Drug Administration posted a warning recently about a counterfeit version of Adderall, the medication taken for ADHD disorder.

Since about 80% of the active ingredients in many medications are produced overseas, there’s plenty of opportunity for counterfeiting along the convoluted and diverse supply chain. Things like adulterated ingredients, substitution of ingredients, or reduced levels of active ingredients, are all too common an occurrence.

The problem of counterfeit drugs is a real and growing problem, especially when drugs are purchased online. The FDA’s efforts to deal with counterfeit drugs are hamstrung because 1) they lack authority to dispose of counterfeits in a quick and efficient way, 2) the penalties for creating or selling fake drugs are not effective enough to deter the activity, and 3) drug importers are not required to track and trace all medications throughout the manufacturing process.

The House and Senate are working on bills to resolve these issues. The House bill grants the FDA authority to require drug manufacturers to provide information about supply problems that could lead to shortages of a particular drug. Currently, this information is given voluntarily, but shortages of particular drugs, such as the cancer drug Avastin, have been in such short supply as to pose serious risk to patients.

Both bills provide for higher fees from drug manufacturers–including, for the first time, generic drug makers, to speed reviews. The fees will make up nearly half the agency’s $4.5 billion budget next year. The Senate version includes a steep increase the penalty for counterfeiting drugs, up to 20 years in prison or a $4 million fine. Recently, the House passed its version of the FDA reauthorization law to give the agency greater powers to inspect foreign manufacturing facilities or block their products if they refuse and to manage drug shortages.

But there are differences between the House and Senate versions of this bill, especially concerning the level of supply-chain tracking that will be required of the pharmaceutical industry to protect against counterfeit medications. The FDA wants a system to track small quantities from manufacturing to pharmacies; something the industry says is too expensive. The industry is backing a plan that tracks lots instead of individual containers. They say it could be refined later to track smaller quantities. The plan put up by an industry coalition would put unique serial numbers on individual drug packages, but require scanning drugs only in “lots” when they get to distributors.

Differences in both versions of the FDA reauthorization law are expected to be resolved by the end of June.

Share Button

Speak Your Mind